Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
860 participants
OBSERVATIONAL
2022-03-01
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This project aims to evaluate a new camera-based system for contactless measurement of vital signs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Noncontact Vital Sign Monitoring Using IR-UWB Radar
NCT03622996
Non Contact Measurement of Vital Signs
NCT02287220
Vital Signs Monitoring of Emergency Responders in Different States
NCT06076057
Predictive Value of Sublingual Microcirculation and Peripheral Tissue Oxygen Monitoring
NCT03859726
Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems
NCT07296419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A method comparison design with three work packages (WP):
WP1: Focus on estimating validity and reliability of the new study device to measure body temperature.
WP2: Focus on estimating validity and reliability of the new study device to measure all vital signs except body temperature (pulse, systolic and diastolic blood pressure, respiratory rate and oxygen saturation).
WP3: Focus on estimating if there is any difference in the validity and reliability of the new study device to measure all vital signs (except body temperature) in subjects with Fitzpatrick skin type 5-6 as compared with those of skin type 1-4.
STUDY POPULATION:
WP1: Patients aged ≥18 years admitted to or attending a hospital clinic. WP2: Patients aged ≥18 year attending primary health care or patients being admitted to a hospital clinic.
WP3: Individuals aged ≥18 years attending primary health care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants
All participants will have their vital signs measured with conventional techniques as well as with the new experimental medical device (labelled RIA-VS)
RIA-VS
Measuring vital signs with a new contactless camera technique
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RIA-VS
Measuring vital signs with a new contactless camera technique
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
WP1+WP2:
1. The patient is attending primary or secondary health care.
2. The subject has provided informed consent.
3. Age ≥18 years.
4. Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions).
5. The patient is willing and able to give informed consent ".
6. The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety.
7. The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included.
WP3:
1. Patients attending primary health care.
2. The subject has provided informed consent.
3. Age ≥18 years.
4. Fluent in Swedish, English, Somali or Arabic (we will translate the patient information and ensure an interpreter can be present for translating questions).
5. The patient is willing and able to give informed consent .
6. The investigator determines that the new study device, and the reference methods, can be used as intended with adequate safety.
7. The delay in the management of each patient introduced by this study is approximately 15-20 minutes. Patients deemed being in such a severe medical condition that 15-20 minutes of delay is deemed detrimental will not be included.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Göteborg University
OTHER
Vastra Gotaland Region
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ronny Gunnarsson, MD PhD
Role: PRINCIPAL_INVESTIGATOR
School of Public Health and Community Medicine, Gothengurg University, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hälsobrunnen Vårdcentral
Ulricehamn, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1261-8273
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.